传染病信息2024，Vol.37Issue(4) ：323-328.DOI:10.3969/j.issn.1007-8134.2024.04.007

免疫检查点抑制剂联合抗血管生成药治疗乙型肝炎相关不可切除肝细胞癌的疗效及安全性

Efficacy and safety of immune checkpoint inhibitors plus antiangiogenic agents for chronic hepatitis B-associated unresectable hepatocellular carcinoma

刘丹 王莉琳 任姗 侯维 马丽娜 郑素军 鲁俊锋
传染病信息2024，Vol.37Issue(4) ：323-328.DOI:10.3969/j.issn.1007-8134.2024.04.007
✕
  • 维普
  • 万方数据

免疫检查点抑制剂联合抗血管生成药治疗乙型肝炎相关不可切除肝细胞癌的疗效及安全性

Efficacy and safety of immune checkpoint inhibitors plus antiangiogenic agents for chronic hepatitis B-associated unresectable hepatocellular carcinoma

刘丹 1王莉琳 1任姗 1侯维 1马丽娜 1郑素军 1鲁俊锋1
扫码查看

作者信息

  • 1. 100069,首都医科大学附属北京佑安医院肝病中心一科
  • 折叠

摘要

目的 探讨免疫检查点抑制剂联合抗血管生成药治疗乙型肝炎相关不可切除肝细胞癌(unresectable hepatocellular carcinoma,uHCC)的疗效及安全性.方法 将2019年7月至2023年7月期间在首都医科大学附属北京佑安医院住院并接受免疫检查点抑制剂联合抗血管生成药治疗的85例乙型肝炎相关uHCC患者纳入研究,收集其临床资料,对疗效和安全性进行回顾性分析.结果 85例uHCC患者中男性65例,女性20例,中位年龄60.0岁,中国肝癌分期方案(China Liver Cancer Staging,CNLC)Ⅲ期者54例(63.5％),血管侵犯者37例(43.5％),远处转移者37例(43.5％),肝功能Child-Pugh B～C级者共28例(32.9％).经治疗6例(7.1％)完全缓解,28例(32.9％)部分缓解,客观应答率可达40.0％,中位无进展生存期为5.8个月(95％CI:4.0～7.7),中位总生存期为25.8个月(95％CI:16.4～35.2).单因素分析显示年龄<55岁、Child-Pugh B～C级、有血管侵犯、CNLC分期Ⅲ～Ⅳ期患者的中位总生存期明显低于年龄≥55岁、Child-Pugh A级、无血管侵犯、CNLC分期Ⅰ～Ⅱ期的患者(P<0.05).总体安全性良好,≥3级不良事件发生率为32.9％.结论 免疫检查点抑制剂联合抗血管生成药治疗uHCC可延长患者的生存期,安全性良好.

Abstract

Objective This study aimed to investigate the efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for patients with chronic hepatitis B associated-unresectable hepatocellular carcinoma (uHCC). Methods Eighty-five patients with uHCC who were hospitalized in Beijing You'an Hospital,Capital Medical University from July 2019 to July 2023 and treated with immune checkpoint inhibitors plus antiangiogenic agents were enrolled. A retrospective study was conducted to analysis the efficacy and safety with clinical data. Results Eighty-five patients with chronic hepatitis B associated-uHCC included 65 males and 20 females,with a median age of 60.0 years old. 54 cases (63.5％) were China Liver Cancer Staging (CNLC) Ⅲ,37 (43.5％) were vascular invasion,37 (43.5％) were distant metastases and 28 (32.9％ ) were Child-Pugh B and C diseases. After treatment,6 cases (7.1％) had complete responses,28 (32.9％) had partial responses,and the objective response rate reached 40.0％. The median progression-free survival was 5.8 months (95％ CI:4.0-7.7),and the median overall survival was 25.8 months (95％ CI:16.4-35.2). Univariate analysis showed that the median OS of the subgroups of patients who were under 55 years old,Child-Pugh BC diseases,vascular invasion and CNLC Ⅲ-Ⅳ were significantly lower than that of patients who were over 55 years old,Child-Pugh A disease,no vascular invasion and CNLC Ⅰ-Ⅱ(P<0.05). The overall safety profile was good,with a grade ≥3 adverse event rate of 32.9％. Conclusions The combination of immune checkpoint inhibitor and antiangiogenic agents can prolong the survival of the patients with chronic hepatitis B associated-uHCC and show a good safety.

关键词

免疫检查点抑制剂/抗血管生成药物/乙肝肝炎病毒/肝癌

Key words

immune checkpoint inhibitors/antiangiogenic agents/hepatitis B virus/hepatocellular carcinoma

引用本文复制引用

基金项目

北京市自然科学基金面上项目(7232080)

首都临床特色诊疗技术研究及转化应用(Z221100007422063)

出版年

2024
传染病信息
解放军第三0二医院

传染病信息

CSTPCD
影响因子：1.366
ISSN：1007-8134
段落导航相关论文